These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24413533)

  • 1. Future opportunities in cancer nanotechnology--NCI strategic workshop report.
    Grodzinski P; Farrell D
    Cancer Res; 2014 Mar; 74(5):1307-10. PubMed ID: 24413533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances from the National Cancer Institute Alliance for Nanotechnology in Cancer.
    Farrell D; Alper J; Ptak K; Panaro NJ; Grodzinski P; Barker AD
    ACS Nano; 2010 Feb; 4(2):589-94. PubMed ID: 20175564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care.
    Hartshorn CM; Bradbury MS; Lanza GM; Nel AE; Rao J; Wang AZ; Wiesner UB; Yang L; Grodzinski P
    ACS Nano; 2018 Jan; 12(1):24-43. PubMed ID: 29257865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating Nanotechnology into Cancer Care.
    Grodzinski P; Kircher M; Goldberg M; Gabizon A
    ACS Nano; 2019 Jul; 13(7):7370-7376. PubMed ID: 31240914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kindling translational cancer nanotechnology research.
    Chapman S; Panaro NJ; Hinkal GW; Hook SS; Prabhakar U; Ptak K; Farrell D; Grodzinski P
    Nanomedicine (Lond); 2012 Mar; 7(3):321-5. PubMed ID: 22385196
    [No Abstract]   [Full Text] [Related]  

  • 6. Trends and patterns in cancer nanotechnology research: A survey of NCI's caNanoLab and nanotechnology characterization laboratory.
    Ke W; Crist RM; Clogston JD; Stern ST; Dobrovolskaia MA; Grodzinski P; Jensen MA
    Adv Drug Deliv Rev; 2022 Dec; 191():114591. PubMed ID: 36332724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The solid progress of nanomedicine.
    Martins JP; das Neves J; de la Fuente M; Celia C; Florindo H; Günday-Türeli N; Popat A; Santos JL; Sousa F; Schmid R; Wolfram J; Sarmento B; Santos HA
    Drug Deliv Transl Res; 2020 Jun; 10(3):726-729. PubMed ID: 32141035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Carolina Center of Cancer Nanotechnology Excellence: past accomplishments and future perspectives.
    Juliano RL; Sunnarborg S; DeSimone J; Haroon Z
    Nanomedicine (Lond); 2011 Jan; 6(1):19-24. PubMed ID: 21182415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of nanotechnology in cancer research: review of progress in the National Cancer Institute's Alliance for Nanotechnology.
    Ehdaie B
    Int J Biol Sci; 2007 Jan; 3(2):108-10. PubMed ID: 17304339
    [No Abstract]   [Full Text] [Related]  

  • 10. National Cancer Institute Alliance for nanotechnology in cancer-Catalyzing research and translation toward novel cancer diagnostics and therapeutics.
    Hartshorn CM; Russell LM; Grodzinski P
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Nov; 11(6):e1570. PubMed ID: 31257722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NCI Alliance for Nanotechnology in Cancer - from academic research to clinical interventions.
    Grodzinski P; Liu CH; Hartshorn CM; Morris SA; Russell LM
    Biomed Microdevices; 2019 Mar; 21(2):32. PubMed ID: 30904965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategic workshops on cancer nanotechnology.
    Nagahara LA; Lee JS; Molnar LK; Panaro NJ; Farrell D; Ptak K; Alper J; Grodzinski P
    Cancer Res; 2010 Jun; 70(11):4265-8. PubMed ID: 20460532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicine: a new frontier in cancer therapeutics.
    Lee PY; Wong KK
    Curr Drug Deliv; 2011 May; 8(3):245-53. PubMed ID: 21291378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy.
    Chaturvedi VK; Singh A; Singh VK; Singh MP
    Curr Drug Metab; 2019; 20(6):416-429. PubMed ID: 30227814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotechnology for cancer diagnostics: promises and challenges.
    Grodzinski P; Silver M; Molnar LK
    Expert Rev Mol Diagn; 2006 May; 6(3):307-18. PubMed ID: 16706735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymmetric-flow field-flow fractionation for measuring particle size, drug loading and (in)stability of nanopharmaceuticals. The joint view of European Union Nanomedicine Characterization Laboratory and National Cancer Institute - Nanotechnology Characterization Laboratory.
    Caputo F; Mehn D; Clogston JD; Rösslein M; Prina-Mello A; Borgos SE; Gioria S; Calzolai L
    J Chromatogr A; 2021 Jan; 1635():461767. PubMed ID: 33310281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NCI Alliance for Nanotechnology in Cancer: achievement and path forward.
    Ptak K; Farrell D; Panaro NJ; Grodzinski P; Barker AD
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(5):450-60. PubMed ID: 20552623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research advancement and prospects of nanotechnology in early diagnosis and treatment of cancer].
    Hu DH; Gong P; Ma YF; Cai LT
    Ai Zheng; 2009 Sep; 28(9):1000-3. PubMed ID: 19728922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detecting and treating cancer with nanotechnology.
    Hartman KB; Wilson LJ; Rosenblum MG
    Mol Diagn Ther; 2008; 12(1):1-14. PubMed ID: 18288878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NCI investment in nanotechnology: achievements and challenges for the future.
    Dickherber A; Morris SA; Grodzinski P
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(3):251-65. PubMed ID: 25429991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.